HWHG(SH:600079) Xin Lang Cai Jing·2025-09-16 08:37Core Viewpoint - The approval of the drug Fluorobiprophenyl injection by the National Medical Products Administration marks a significant milestone for the company, enabling it to sell the product in the domestic market and enhance its product pipeline [1] Group 1: Product Approval and Market Potential - The company's subsidiary, Yichang Renfu Pharmaceutical Co., Ltd., received the drug registration certificate for Fluorobiprophenyl injection, which is indicated for postoperative and cancer pain relief [1] - The company submitted a marketing authorization application for the drug in December 2023, which has been accepted [1] - The estimated national sales for Fluorobiprophenyl injection in 2024 are approximately 980 million yuan [1] Group 2: Research and Development Investment - The cumulative research and development investment for the drug amounts to around 35 million yuan [1] Group 3: Market and Regulatory Environment - The approval signifies the company's qualification to sell the drug in the domestic market, but future sales may be influenced by industry policies and market conditions, indicating uncertainty [1]